Bausch Health Companies Inc. Stock
$6.91
9.26%
today
NYSE,
Sep 16, 08:18 pm CET
Bausch Health Companies Inc. Stock price
$6.32
+0.84
15.33%
1M
-2.96
31.90%
6M
-1.70
21.20%
YTD
-2.31
26.77%
1Y
-22.87
78.35%
3Y
-16.92
72.81%
5Y
-115.11
94.80%
10Y
NYSE,
Closing price Fri, Sep 13 2024
+0.02
0.32%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $2.32b |
| Enterprise Value | $24.31b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 26.62 |
| EV/Sales (TTM) EV/Sales | 2.64 |
| P/S ratio (TTM) P/S ratio | 0.25 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 10.20% |
| Revenue (TTM) Revenue | $9.20b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
7 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
7 Analysts have issued a Bausch Health Companies Inc. forecast:
Buy
14%
Hold
57%
Sell
29%
Financial data from Bausch Health Companies Inc.
| Jun '24 |
+/-
%
|
||
| Revenue | 9,202 9,202 |
10%
10%
|
|
| Gross Profit | 5,436 5,436 |
15%
15%
|
|
| EBITDA | 2,985 2,985 |
9%
9%
|
EBIT (Operating Income) EBIT | 1,717 1,717 |
22%
22%
|
| Net Profit | -471 -471 |
153%
153%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Positive
Market Watch
●
about 7 hours ago
Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.
Neutral
Accesswire
●
5 days ago
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 CABTRE...
Neutral
Accesswire
●
about one month ago
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Heal...
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,270 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
